Is Product Infatuation the Death Knell for Platforms?
Incyte Genomics Inc., the creator of the database model and practically the ur-platform company, has suddenly decided to turn into a drug discovery company--changing top management to do so. Other firms that decided years ago to leverage genetic information to create drugs have far higher valuations than Incyte--indeed biotechs reporting product revenues get valuation multiples on sales that are twice as high as those platform companies command --and about triple the multiples that Big Pharma receives on its sales.
You may also be interested in...
2001 was a mixed year for health-care manufacturers, characterized by real advances in cardiac device therapies, the maturing of the biotech and generics sectors, and the continued embattlement of Big Pharma. Here's the staff of IN VIVO's list of the most important trends.
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
Regulators want to help smooth the process of bringing a gene therapy to market, hoping to iron out ‘surprises’ and even address reimbursement issues for the sake of patients.